Sector News

Bayer to cut 200 jobs at U.S. logistics center

February 22, 2019
Life sciences

Add a Bayer Healthcare logistics center in Indiana to U.S. operations that will get whacked as part of a major restructuring that will hive off its animal health unit and shed about 12,000 jobs.

The German company this week told about 195 employees at the center in Mishawaka that the operation will be closed over the next 18 months.

Bayer spokesman Chris Loder said in an email today that the decision to close the Indiana site was part of its effort to transition toward an integrated global organization and increase efficiency.

“Most of the employees at the Mishawaka/Edison Lakes site are part of Bayer’s customer logistics service center, which is responsible for the end-to-end customer experience—from the starting point of taking customer orders, through to delivery and final payment—for our Consumer Health and Pharmaceuticals businesses.”

The German conglomerate has already announced other closings across its diverse organization. It has said that it will close its hemophilia manufacturing facility in Wuppertal, Germany, and lay off 350 workers, focusing all of its recombinant factor VIII production at its site in Berkeley, California. The cuts in Germany came on top of the announced layoffs in October of more than 225 manufacturing workers in Berkeley.

Last month, it said it was closing an operations center in Robinson, Pennsylvania, near Pittsburgh, that was part of its decision to consolidate business functions. The cuts mean the loss of 569 Bayer employees and 96 contractors over the next two years. Other cuts include a decision to divest its animal health business and to shed part of its consumer health franchise—along with 1,100 jobs in the sector. It also will trim 4,100 crop science positions as it integrates its newly acquired Monsanto operations.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend